Working… Menu

Post Approval Registry of Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar (CELESTIAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00810264
Recruitment Status : Completed
First Posted : December 18, 2008
Last Update Posted : December 19, 2018
Information provided by (Responsible Party):
Biotronik, Inc.

Brief Summary:
The objective of this study is to confirm the long-term safety and reliability of the Corox OTW BP left ventricular (LV) pacing lead. As a condition of approval, the FDA required that a registry documenting the post approval clinical experience of these leads be designed and implemented.

Condition or disease Intervention/treatment
Congestive Heart Failure Device: CRT Therapy - LV Lead Registry

Detailed Description:

This study is an FDA-required, multi-center, prospective, non-randomized, data collection registry. Eligible patients must have been successfully implanted with a Corox OTW BP, Corox OTW-S BP, or Corox OTW-L BP LV lead with a BIOTRONIK CRT device and consented and enrolled between 7-180 days following implant. At least 2500 patients will be enrolled in this post-approval registry, and each patient will be followed for five years post-implant.

Safety will be evaluated based on the analysis of the overall incidence of lead-related adverse events that require additional invasive intervention. In addition, each individual adverse event will be separately investigated. Lead parameters for sensing, pacing thresholds, and impedance will also be evaluated. Reporting of all adverse events will be performed twice a year in order to identify and characterize any trends in adverse events, failure modes, or failure rates.

Layout table for study information
Study Type : Observational
Actual Enrollment : 2499 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: CELESTIAL Post Approval Registry: Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar Post Approval Registry
Study Start Date : December 2008
Actual Primary Completion Date : November 2, 2018
Actual Study Completion Date : November 2, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Group/Cohort Intervention/treatment
Data Collection Group Device: CRT Therapy - LV Lead Registry
Collecting long-term safety and efficacy data on a market-released left ventricular lead.

Primary Outcome Measures :
  1. Overall complication-free rate [ Time Frame: 5 years ]
  2. Individual complication rates [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients will be obtained from the investigators' general patient population according to the inclusion and exclusion criteria described below.

Inclusion Criteria:

  • Successfully implanted BIOTRONIK CRT system, including a Corox BP LV lead, from 7-180 days prior to enrollment
  • Able to understand the nature of the registry and give informed consent
  • Available for follow-up visits on a regular basis at the investigational site
  • Age greater than or equal to 18 years

Exclusion Criteria:

  • Enrolled in any IDE clinical study
  • Planned cardiac surgical procedures or interventional measures within the next 6 months
  • Expected to receive a heart transplant within 1 year
  • Life expectancy less than 1 year
  • Presence of another life-threatening, underlying illness separate from their cardiac disorder
  • Pregnancy
  • Inability to provide date of implant, devices implanted, age, gender, and whether the patient experienced any protocol-defined adverse events since implant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00810264

  Hide Study Locations
Layout table for location information
United States, Alabama
Birmingham, Alabama, United States
United States, Arizona
Glendale, Arizona, United States
Mesa, Arizona, United States
Phoenix, Arizona, United States
Scottsdale, Arizona, United States
Tucson, Arizona, United States
United States, California
Anaheim, California, United States
Fairfield, California, United States
Fountain Valley, California, United States
Glendale, California, United States
Hawthorne, California, United States
Inglewood, California, United States
Los Angeles, California, United States
National City, California, United States
Northridge, California, United States
Orange, California, United States
Rancho Mirage, California, United States
Santa Barbara, California, United States
Torrance, California, United States
Ventura, California, United States
Watsonville, California, United States
United States, Colorado
Aurora, Colorado, United States
Boulder, Colorado, United States
United States, Connecticut
Danbury, Connecticut, United States
United States, Florida
Brooksville, Florida, United States
Davenport, Florida, United States
Melbourne, Florida, United States
Naples, Florida, United States
New Smyrna Beach, Florida, United States
Saint Petersburg, Florida, United States
Tampa, Florida, United States
United States, Georgia
Macon, Georgia, United States
United States, Illinois
Urbana, Illinois, United States
United States, Indiana
Fort Wayne, Indiana, United States
Valparaiso, Indiana, United States
United States, Kentucky
Owensboro, Kentucky, United States
United States, Louisiana
Covington, Louisiana, United States
Hammond, Louisiana, United States
Lafayette, Louisiana, United States
United States, Maine
Bangor, Maine, United States
United States, Maryland
Baltimore, Maryland, United States
Cumberland, Maryland, United States
Lanham, Maryland, United States
Rockville, Maryland, United States
United States, Massachusetts
Burlington, Massachusetts, United States
Worcester, Massachusetts, United States
United States, Michigan
Ann Arbor, Michigan, United States
Lansing, Michigan, United States
Lapeer, Michigan, United States
Saginaw, Michigan, United States
Wyoming, Michigan, United States
Ypsilanti, Michigan, United States
United States, Mississippi
Tupelo, Mississippi, United States
United States, Missouri
Crystal City, Missouri, United States
Saint Louis, Missouri, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New Jersey
Glen Ridge, New Jersey, United States
United States, New York
New York, New York, United States
Rochester, New York, United States
United States, North Carolina
Gastonia, North Carolina, United States
Winston-Salem, North Carolina, United States
United States, Ohio
Columbus, Ohio, United States
Middletown, Ohio, United States
Steubenville, Ohio, United States
Toledo, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Oregon
Salem, Oregon, United States
United States, Pennsylvania
Chinchilla, Pennsylvania, United States
Lancaster, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pottstown, Pennsylvania, United States
Yardley, Pennsylvania, United States
United States, South Carolina
Columbia, South Carolina, United States
Greenville, South Carolina, United States
Spartanburg, South Carolina, United States
United States, Tennessee
Chattanooga, Tennessee, United States
United States, Texas
Amarillo, Texas, United States
Brownsville, Texas, United States
Corpus Christi, Texas, United States
Dallas, Texas, United States
Kingwood, Texas, United States
McKinney, Texas, United States
Nacogdoches, Texas, United States
United States, Virginia
Fredericksburg, Virginia, United States
United States, Washington
Spokane, Washington, United States
Yakima, Washington, United States
Sponsors and Collaborators
Biotronik, Inc.

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Biotronik, Inc. Identifier: NCT00810264     History of Changes
Other Study ID Numbers: CELESTIAL
First Posted: December 18, 2008    Key Record Dates
Last Update Posted: December 19, 2018
Last Verified: December 2018
Keywords provided by Biotronik, Inc.:
Long-term safety and reliability of a bipolar left ventricular lead on congestive heart failure patients
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases